These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

843 related items for PubMed ID: 16914971

  • 21. Natalizumab for multiple sclerosis: a complicated treatment.
    Keegan BM.
    Lancet Neurol; 2011 Aug; 10(8):677-8. PubMed ID: 21777819
    [No Abstract] [Full Text] [Related]

  • 22. [Monoclonal antibodies in multiple sclerosis].
    Papeix C, Lubetzki C.
    Med Sci (Paris); 2009 Dec; 25(12):1113-5. PubMed ID: 20035688
    [Abstract] [Full Text] [Related]

  • 23. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
    Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P.
    N Engl J Med; 2005 Jul 28; 353(4):362-8. PubMed ID: 15947080
    [Abstract] [Full Text] [Related]

  • 24. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
    Alvarez-Cermeño JC, Masjuan J, Villar LM.
    N Engl J Med; 2005 Oct 20; 353(16):1744-6; author reply 1744-6. PubMed ID: 16240475
    [No Abstract] [Full Text] [Related]

  • 25. Natalizumab for relapsing multiple sclerosis.
    Tenser RB.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16738278
    [No Abstract] [Full Text] [Related]

  • 26. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP.
    Ned Tijdschr Geneeskd; 2007 Apr 14; 151(15):852-5. PubMed ID: 17472115
    [Abstract] [Full Text] [Related]

  • 27. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.
    Arch Neurol; 2010 Nov 14; 67(11):1391-4. PubMed ID: 20625069
    [Abstract] [Full Text] [Related]

  • 28. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH.
    Neurology; 2011 Feb 08; 76(6):574-6. PubMed ID: 21300973
    [No Abstract] [Full Text] [Related]

  • 29. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK.
    Arch Neurol; 2006 Oct 08; 63(10):1383-7. PubMed ID: 17030653
    [Abstract] [Full Text] [Related]

  • 30. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.
    J Neuroimaging; 2014 Oct 08; 24(4):425-8. PubMed ID: 23323645
    [Abstract] [Full Text] [Related]

  • 31. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C.
    N Engl J Med; 2009 Sep 10; 361(11):1081-7. PubMed ID: 19741229
    [Abstract] [Full Text] [Related]

  • 32. Natalizumab for relapsing multiple sclerosis.
    Jeffery DR.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
    [No Abstract] [Full Text] [Related]

  • 33. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil SS, Weber MS, Frohman EM, Kleinschmidt-Demasters BK, Montine TJ, Hemmer B, Marra CM, Stüve O.
    Arch Neurol; 2009 Aug 01; 66(8):1016-20. PubMed ID: 19667224
    [Abstract] [Full Text] [Related]

  • 34. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
    Keeley KA, Rivey MP, Allington DR.
    Ann Pharmacother; 2005 Nov 01; 39(11):1833-43. PubMed ID: 16219898
    [Abstract] [Full Text] [Related]

  • 35. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R, Jelčić I, Schippling S, Martin R, Sospedra M.
    Eur J Immunol; 2012 Mar 01; 42(3):790-8. PubMed ID: 22144343
    [Abstract] [Full Text] [Related]

  • 36. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.
    Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, Bozic C, Richman S.
    Neurology; 2011 May 17; 76(20):1697-704. PubMed ID: 21576685
    [Abstract] [Full Text] [Related]

  • 37. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
    Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, Gold R.
    Mult Scler; 2013 Feb 17; 19(2):249-51. PubMed ID: 22596228
    [Abstract] [Full Text] [Related]

  • 38. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.
    Langer-Gould A, Steinman L.
    Curr Neurol Neurosci Rep; 2006 May 17; 6(3):253-8. PubMed ID: 16635435
    [Abstract] [Full Text] [Related]

  • 39. Natalizumab and progressive multifocal leukoencephalopathy.
    Adelman B, Sandrock A, Panzara MA.
    N Engl J Med; 2005 Jul 28; 353(4):432-3. PubMed ID: 15947083
    [No Abstract] [Full Text] [Related]

  • 40. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.
    Mult Scler; 2013 Dec 28; 19(14):1826-40. PubMed ID: 24192217
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.